Acetylcholinesterase inhibitors (AChEi) are commonly used for symptomatic management of Alzheimer's Disease and are suggested to have potential disease-modifying effects, including regulating myelin state. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.